UroGen Pharma Ltd (NASDAQ:URGN) price on Thursday, June 12, rose 51.78% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $11.08.
A look at the stock’s price movement, the close in the last trading session was $7.30. Turning to its 52-week performance, $20.70 and $3.42 were the 52-week high and 52-week low respectively. Overall, URGN moved 9.27% over the past month.
UroGen Pharma Ltd’s market cap currently stands at around $510.86 million, with investors looking forward to this quarter’s earnings report slated for in July.
Analysts have a consensus estimate of 22.89M for the company’s revenue for the quarter, with a low and high estimate of 20.86M and 25.9M respectively. The average forecast suggests up to a 4.79% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 112.52M, representing a 24.47% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that URGN is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend URGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
URGN’s current price about 83.11% and 27.92% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 69.20, while 7-day volatility ratio is 21.30% and 20.38% in the 30-day chart. Further, UroGen Pharma Ltd (URGN) has a beta value of 0.43, and an average true range (ATR) of 1.31. Analysts have given the company’s stock an average 52-week price target of $40, forecast between a low of $22 and high of $60. Looking at the price targets, the low is -98.56% off current price level while to achieve the yearly target high, price needs to move -441.52%. Nonetheless, investors will most likely welcome a -261.01% jump to $40 which is the analysts’ median price.
If we refocus on UroGen Pharma Ltd (NASDAQ:URGN), historical trading data shows that trading volumes averaged 1.73 million over the past 3 months. The company’s latest data on shares outstanding shows there are 46.10 million shares.
The 15.66% of UroGen Pharma Ltd’s shares are in the hands of company insiders while institutional holders own 91.87% of the company’s shares. Current price change has pushed the stock 4.04% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the URGN stock continues to rise going into the next quarter.
